Proteas Bioanalytics Inc.
From a single drop of blood, Proteas Bioanalytics is able to detect the presence of human diseases at their earliest stage, before the onset of symptoms. Our technologies will also provide objective guidance to implement effective treatment options.
Proteas Bioanalytics has also developed advanced technologies for the in-depth analysis and biological understanding of single cells and tissue biopsy specimens that complement and validates our blood-based analysis platform.
The field of blood and single-cell proteomics offers a tremendous opportunity to reshape the diagnosis and treatment of almost all diseases. Currently used proteomics technologies do not meet the stringent FDA performance criteria due to the high complexity and heterogeneity of human blood, tissue and cells and their analysis method.
The Proteas Bioanalytics proprietary proteomics technology:
▪ includes the analysis of all proteins expressed in blood, cells and tissues during healthy or diseased situations
▪ leverages 30-years of our published methods and overcomes previous limitations
▪ leads to the development of novel protein-based biological signatures with actionable clinical importance
▪ leads to the development of novel proteins markers for monitoring the response to treatment (pharmacology, immunotherapy, nutritional intervention, lifestyle intervention)
➢ We are both a platform and disease-specific biosignature with assay development company
➢ Our core proteomics technology can be partnered across indications to pharma and biotech companies, while our internal biomarker platforms will be developed for high unmet needs in the clinical arena
The Proteas Bioanalytics team has extensive industrial, academic, and government experience in research and development, partnering, biology, pharmacology, analytical chemistry, nanotechnology, mathematics and artificial intelligence that will promotes the development of a state-of-the-art and innovative platforms.
